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published by libertas academica. learn more about this journal. 2 This therapy comprised the following protocol 2 : 50 µg once weekly for 2 weeks, then 135 µg once weekly for 6 weeks, and finally 135 µg every 2 weeks.
Our patient showed hematological remission in terms of normalization of WBCs because her WBC count remained below 11,000; her platelets were normal and remained so all through the treatment and her Hb level remained .10 g/dL, with no symptoms or infections and with excellent clinical condition. The patient was offered a repeat bone marrow test but she was reluctant. As per our knowledge, this is the first case report with interferon alpha2a; what was reported previ ously by Meyer et al. 3 was therapy using interferon alpha 2b.
discussion
Myeloproliferative disorders comprise a range of conditions, ie, BCRABLpositive chronic myelogenous leukemia (CML), CNL, polycythemia vera, primary myelofibrosis, essential thromobocythemia, chronic eosinophilic leukemia not oth erwise specified, mastocytosis, and unclassifiable MPN. 4 In the WHO classification of myeloid disorders, CNL is rec ognized as an MPN characterized by sustained neutrophilic leukocytosis, hepatosplenomegaly, and bone marrow granulo cytic hyperplasia without evidence of dysplasia, BCRABL1, or rearrangements of PDGFRa, PDGFRb, or FGFR1. This diagnosis is dependent on the exclusion of underlying causes of reactive neutrophilia, particularly if evidence of myeloid clonality is lacking. The lack of a specific molecular marker has left the diagnosis to be largely one of exclusion. Recently, the molecular landscape shifted with the discovery of specific oncogenic mutations in the CSF3R in CNL patients. 5 Being a diagnosis of exclusion, CNL identification is difficult for both clinician and pathologist. Our patient presented with leukocy tosis. In clinical practice, neutrophilia most commonly relates to leukemoid reactions due to chronic infections, inflamma tory diseases, or various types of malignancies. 6 In our patient, there were no symptoms or signs of inflam mations, and PET/CT scanning was performed to rule out hidden malignancies, the result of which was negative. Clini copathologic characteristics of CML include splenomegaly and a neutrophilic leukocytosis with left shift, and these were ruled out by negative BCRABL, absence of Philadelphia chromosome, and normal cytogenetic analysis. Negative JAK2 V617F helps to exclude other myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Myeloid neoplasm with PDGFRa and PDGFRβ were ruled out by the negative results for molecular markers. CNL is a rare MPN, with only ∼200 patients reported to date, mostly from case reports and small case series. Abbreviations: Who, World health organization; Cnl, chronic neutrophilic leukemia; aCMl, atypical chronic myelogenous leukemia, BCR-aBl1 negative; WBC, white blood cell; Ph, Philadelphia chromosome; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; PV, polycythemia vera; ET, essential thrombocythemia; PM, primary myelofibrosis; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; v, patient meets criterion; X, patient does not meet criterion.
50%-60% of patients with CNL or aCML harbor mutations in the receptor for CSF3R (GCSFR). Under normal circum stances, the CSF3R ligand, granulocytecolonystimulating factor (GCSF), promotes growth and survival of myeloid precursor cells, ultimately leading to differentiation of these myeloid precursors into neutrophils. Deletion of CSF3R leads to neutropenia in mouse models. 7 In addition to regulating normal neutrophil homeostasis, GCSF levels rapidly increase during infection, resulting in elevated levels of neutrophils as a component of the immune response. 8 The normal role of CSF3R in promoting neutrophil production is biologically consistent with our observation of CSF3R activating muta tions in hematologic malignancies characterized by high levels of neutrophils. Our patient was tested for this mutation and found to be negative. The absence of hepatosplenomegaly is not against CNL. Persistence of neutrophilia for more than 1 year and absence of all secondary causes make CNL the most likely diagnosis because its diagnosis is only by exclusion. Additional factors of CNL usually present with splenomegaly but absence of splenomegaly, normal cytogenetics, and molecular markers that rule out CNL are not seen.
No standard of care exists for CNL or aCML. Therapy has primarily consisted of cytoreduction by hydroxyurea or other oral chemotherapeutics, as well as use of interferona. [9] [10] [11] These agents can elicit improvement in blood counts but exhibit no proven diseasemodifying benefit. Although splenic irra diation and splenectomy may provide transient palliation of symptomatic splenomegaly, the latter has been associated with anecdotal worsening of neutrophilic leukocytosis in CNL. The limited experience with inductiontype chemotherapy for blastic transformation is generally poor, with death related to resistant disease or regimenrelated toxicities. Allogeneic transplantation may result in favorable longterm outcomes in selected patients, particularly when undertaken in the chronic phase of disease. 9 Our patient, who was recently married few months before diagnosis, required different treatment options. These options were explained to her, and she opted for pegy lated interferon alpha2a. This therapy was started as per Yassin et al. 2 The treatment was well tolerated by the patient and she successfully achieved good hematological response.
In summary, even in the era of molecular testing, in the case of this woman in her 40s, the diagnosis of CNL rep resents a diagnostic difficulty. In addition, the treatment of CNL remains experimental, with no standard of care due to the nature of the disease and its rarity. 
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